- The Wall Street Journal•2 days ago
U.S. regulators approved Amgen Inc.’s copy of the AbbVie Inc.’s anti-inflammatory treatment, Humira, which was the second-biggest selling drug in 2015.
- Associated Press•2 days ago
Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory ...
- PR Newswire•2 days ago
THOUSAND OAKS, Calif., Sept. 23, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||174.55 x 100|
|Ask||175.10 x 100|
|Day's Range||174.61 - 176.85|
|52wk Range||130.09 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.89|
|Avg Vol (3m)||2,864,382|
|Dividend & Yield||4.00 (2.29%)|